Akcije

Archive of Oncology
kako citirati ovaj članak
podeli ovaj članak

Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 3 od 4  
Back povratak na rezultate
2020, vol. 26, br. 1, str. 10-15
Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
(naslov ne postoji na srpskom)
aUniverzitetska bolnica Foča, Republika Srpska, BiH + Univerzitet u Istočnom Sarajevu, Medicinski fakultet, Foča, Republika Srpska, BiH
bKlinički centar Republike Srpske, Klinika za onkologiju, Banja Luka, Republika Srpska, BiH
cUniverzitet u Istočnom Sarajevu, Medicinski fakultet, Foča, Republika Srpska, BiH

e-adresanikolina.dukic1981@gmail.com
Ključne reči: cancer; breast; tyrosine kinase receptor; HER2; trastuzumab; prognosis; antibodies
Sažetak
(ne postoji na srpskom)
Background: Of all breast cancers 20-25% are HER2 positive. Overexpression of HER2 protein on the surface of the malignant cell leads to excessive cell proliferation through different signaling pathways. Trastuzumab is a human monoclonal antibody that binds to domain IV of HER2 receptor and blocks signaling pathway for proliferation. The result is an improved prognosis for HER 2 positive breast cancer patients, even when compared to patients with other types of breast cancers. Methods: The study presents 74 women patients with early HER2 positive breast cancer who were previously operated (either radicaly or using breast conserving surgery), and received adjuvant chemoand radiotherapy. Fourty four patients received adjuvant trastuzumab for one year, and 30 patients did not (control group). Observed time to relapse of the disease was 60 months. Results: There was a significant difference in survival in favor of the group that received trastuzumab (p<0.001). Application of trastuzumab also delayed relapse of the disease by 51.7%. No significant difference was observed between estrogen receptor positive and estrogen receptor negative cancers., In the control group there was a significant difference in relapse free survival in favor of estrogen and progesteron receptor positive tumors (p<0.001). Conclusion: Survival of patients with a HER2 positive breast cancer whose prognosis was initially worse compared to HER2 negative patients, significantly improved after administration of trastuzumab.
Reference
*** (2007) Cancer registry Republic of Srpska. Banja Luka: Institut za zaštitu zdravlja Republike Srpske
Advisory Committee On Cancer Prevention (2000) Recommendations on cancer screening in the European Union. European Journal of Cancer, 36(12), 1473-1478
Braga, S., Dal, L.L., Bernard, C., Cardoso, F., Piccart, M. (2006) Use of trastuzumab for the treatment of early stage breast cancer. Expert review of anticancer therapy, 6(8), 1153-1164
Cardoso, F., di Leo, A., Lohrisch, C., Bernard, C., Ferreira, F., Piccart, M.J. (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades?. Annals of Oncology, 13(2), 197-207
Chevallier, B., Heintzmann, F., Mosseri, V., Dauce, J.P., Bastit, P., Graic, W., Asselain, B. (1988) Prognostic value of estrogen and progesterone receptors in operable breast cancer: Results of a univariate and multivariate analysis. Cancer, 62(12), 10.1002/1097-0142(19881215)62:12<2517::aid-cncr2820621211>3.0.co
de Azambuja, E., Ponde, N.F., Procter, M.J., Rastogi, P., Cecchini, R.S., Ballman, K.V., Moreno-Aspitia, A., Zardavas, D., Roca, L., Gelber, R.D., Piccart, M., Suter, T.M. (2018) Meta-analysis of the cardiac events in the adjuvant trastuzumab trials. Journal of Clinical Oncology, 36(15), 10066-10066
Delord, J.P., Allal, C., Canal, M., Mery, E., Rochaix, P., Hennebelle, I., Canal, P. (2005) Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Annals of Oncology, 16(12), 1889-1897
Ferlay, J., Bray, F., Pisani, P., Parkin, D.M. (2002) Globocan 2002: Cancer incidence, mortality and prevalence worldwide. u: IARC Cancerbase No 5, version 2.0, Lyon, France
Fuqua, S.A., Schiff, R., Parra, I., Moore, J.T., Mohsin, S.K., Osborne, C.K. (2003) Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer research, 63(10), 2434-2439
Gojković, Z. (2009) Prognostički značaj markera neoangiogeneze kod bolesnica sa karcinomima dojke i uticaj na dužinu vremena do pojave recidiva i udaljenih metastaza. Beograd, doktorska disertacija, 21-22
Gojković, Z., Rakita, I., Vranješ, Ž., Nikolić, P., et al. (2012) Ciljana terapija - mjesto monoklonalnih antitijela u terapiji raka dojke - savremeni pristup u tretmanu karcinoma dojke. Zbornik radova Akademije nauka i umjetnosti Bosne i Hercegovine, Sarajevo, 41, 113-133
Goldhirsch, A., Wood, W.C., Gelber, R.D., Coates, A.S., Thürlimann, B., Senn, H.J., et al. (2007) Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of Oncology, 18(7), 1133-1144
Goldhirsch, A., Winer, E.P., Coates, A.S., et al. (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 24, 2206-2223
Jemal, A., Thomas, A., Murray, T., Thun, M. (2002) Cancer Statistics. CA: A Cancer Journal for Clinicians, 52(1), 23-47
Nagata, Y., Lan, K., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., Yu, D. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6(2), 117-127
Piotrowski, G., Gawor, R., Stasiak, A., Gawor, Z., Potemski, P., Banach, M. (2012) Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer over expressing human epidermal growth factor receptor type 2: A prospective study. Archives of Medical Science, 2, 227-235
Pivot, X., Romieu, G., Debled, M., Pierga, J., Kerbrat, P., Bachelot, T., Lortholary, A., Espié, M., Fumoleau, P., Serin, D., Jacquin, J., Jouannaud, C., Rios, M., Abadie-Lacourtoisie, S. (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): A randomised phase 3 trial. Lancet Oncology, 14(8), 741-748
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., Pinter, T., Valero, V., Liu, M., Sauter, G., von Minckwitz, G., Visco, F. (2011) Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine, 365(14), 1273-1283
Slamon, D., Pegram, M. (2001) Rationale for trastuzumab (herceptin) in adjuvant breast cancer trials. Seminars in Oncology, 28(1D), 13-19
Tyczynski, J.E., Bray, F., Parkin, D.M. (2002) Breast cancer in Europe. ENCR Cancer Fact Sheets, 2
Viani, G.A., Afonso, S.L., Stefano, E.J., de Fendi, L.I., Soares, F.V. (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer, 7(1)
Yin, W., Jiang, Y., Shen, Z., Shao, Z., Lu, J. (2011) Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PLoS One, 6(6), e21030-e21030
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/AOO181112006D
objavljen u SCIndeksu: 30.11.2019.
metod recenzije: jednostruko anoniman
Creative Commons License 4.0

Povezani članci

Nema povezanih članaka